ImmuCell
ICCCImmuCell Corporation (NASDAQ: ICCC) is a United States-based biotechnology company operating in the animal health sector. The company's primary business focus is the development, manufacture, and marketing of products designed to improve health and productivity for cattle in the dairy and beef industries. Its commercial activities are centered on creating solutions that address significant health challenges in livestock production. The company's key therapeutic areas include mastitis prevention and scours (diarrhea) management in newborn calves. Its lead product, First Defense®, is a USDA-licensed treatment containing hyperimmune antibodies used for the prevention of enteric colibacillosis, a form of scours caused by E. coli. For the dairy industry, ImmuCell manufactures and sells the Wipe Out® Dairy Wipes product line. Furthermore, the company is developing Re-Tain™, a targeted therapy for the treatment of subclinical mastitis in lactating dairy cows, which is currently under FDA review. As a publicly traded entity, ImmuCell's operations encompass internal development, manufacturing at its facility in Portland, Maine, and direct sales and marketing. The company's product portfolio and pipeline are specifically targeted toward providing biologically derived solutions for production diseases within the ruminant livestock market.
ICCC · Stock Price
Historical price data
About
ImmuCell Corporation (NASDAQ: ICCC) is a United States-based biotechnology company operating in the animal health sector. The company's primary business focus is the development, manufacture, and marketing of products designed to improve health and productivity for cattle in the dairy and beef industries. Its commercial activities are centered on creating solutions that address significant health challenges in livestock production. The company's key therapeutic areas include mastitis prevention and scours (diarrhea) management in newborn calves. Its lead product, First Defense®, is a USDA-licensed treatment containing hyperimmune antibodies used for the prevention of enteric colibacillosis, a form of scours caused by E. coli. For the dairy industry, ImmuCell manufactures and sells the Wipe Out® Dairy Wipes product line. Furthermore, the company is developing Re-Tain™, a targeted therapy for the treatment of subclinical mastitis in lactating dairy cows, which is currently under FDA review. As a publicly traded entity, ImmuCell's operations encompass internal development, manufacturing at its facility in Portland, Maine, and direct sales and marketing. The company's product portfolio and pipeline are specifically targeted toward providing biologically derived solutions for production diseases within the ruminant livestock market.